Canal-U

Mon compte

CHELBI-ALIX Mounira

Statut
Directeur de Recherche.
Parcours
Formation Universitaire :
1976 : Maîtrise de Biologie, Université PARIS VII
1977 : Diplôme d'Etude Approfondies de Biologie Moléculaire, Université PARIS VII
1980 : Thèse de Doctorat de troisième cycle, Université PARIS VII
1987 : Thèse de Doctorat d'Etat es sciences, Université PARIS VII
Adresses professionnelles
1977-1978 :Stage de DEA, IBPC, Laboratoire D. Hayes, 13 rue P. et M. Curie, 75005 Paris
1978- 1980 : Boursière Ligue Nationale Contre le Cancer, IBPC, laboratoire M. Grunberg-Manago. 13 rue P. et M. Curie, 75005 Paris
1981 : Entrée au CNRS au grade de CR2, Chargée de Recherche 2ème classe
1985 : Passage au grade de CR1 Chargée de Recherche 1ère classe
1987-1993 : U245 INSERM, Hôpital St Antoine, 75011 Paris, Responsable de l'équipe“Mécanisme d'induction et d'action des interférons ”
1994-2001 :UPR 9051 CNRS, Hôpital St Louis ,75010 Paris, Responsable de l'équipe “Rôle des corps nucléaires dans la réponse à l'interféron ”
Depuis 1998 Directeur de Recherche 2ème classe CNRS
2001- UPR 9045 CNRS, Institut Lwoff , 7 rue Guy Moquet, 94801 Villejuif
Responsable de l'équipe “Rôle des protéines conjuguées à SUMO dans la réponse à l'interféron et aux agents thérapeutiques ”
Editeur d'un spécial “ Oncogene ” "APL a curable tumor pathology, from RAR to PML nuclear bodies" Edition novembre 2001
Evaluation scientifique
Evaluation d'Unités de recherche CNRS. Referee pour fondations ou associations (AIRC) et pour divers journaux incluant Oncogene, J. Biol. Chem, J. Virol, Exp. Cell Res.
Particularités
LISTE DES PUBLICATIONS
1 - Thang, M.N., Thang, D.C., Chelbi-Alix, M.K., Robert-Galliot, B., Commoy-
Chevalier, M.J. and Chany, C.
Human leukocyte interferon : relationship between molecular structure and
species specificity.
Proc. Natl. Acad. Sci. USA, 1979, 76, 3717-21.
2- Chelbi-Alix, M.K. and Thang, M.N.
Separation of species of human and mouse interferons by polynucleotide -
affinity chromatography.
Methods in Enzymology, 1981, 78, 576-91.
3 -Chelbi-Alix, M.K., Alix, J.H., Expert-Besançon, A., Hayes, F., Branlant, C.
Properties of ribosomes and RNA synthesized by E. Coli grown in the
presence of ethionine ; normal maturation of E. Coli ribosomal RNA in the
absence of methylation.
Eur. J. Biochem., 1981, 115, 627-634.
4 -Chousterman, S., Bird, J., Yao, J.S., Chelbi-Alix, M.K., Giroud, J.P. and
Thang, M.N. 2'5' oligoadenylate synthetase activity level : an interferon-induced
enzyme in macrophage derived from normal or inflamed mice.
Ann. Virol., 1984, 135E, 363-368.
5 -Chousterman, S., Chelbi-Alix, M.K. and Thang, M.N.
Heat-shock induced regulation of 2'5' oligoadenylate synthetase.
Prog. Clin. Biol., 1985, 67-74.
6- Chelbi-Alix, M.K. and Thang, M.N.
Chloroquine impairs the interferon-induced antiviral state without affecting the 2'5'
oligoadenylate synthetase.
J. Biol. Chem., 1985, 260, 7960-7964.
7- Chousterman, S., Chelbi-Alix, M.K. and Thang, M.N.
2'5' oligoadenylate synthetase expression is induced in response to heat-shock.
J. Biol. Chem., 1987, 262, 4806-4811.
8- Chelbi-Alix, M.K. and Thang, M.N.
Multiple molecular forms of interferon display different specific activities in the induction
of the antiviral state and 2'5' oligoadenylate synthetase.
Biochem. Biophys. Res. Commun., 1986, 141, 1042-1050.
9-Chelbi-Alix, M.K. and Thang, M.N.
Cloned human interferons a : differential affinities for polyinosinic acid and relationship
between molecular structure and species specificity.
Biochem. Biophys. Res. Commun., 1987, 145, 426-435.
10-Chousterman, S., Chelbi-Alix, M.K. and Thang, M.N.
2'5'A synthetase activity is induced by a factor excreted in heat-shocked cells.
Comparison of this factor with IFN.
The Biology of the Interferon System (Cantell K. and Schellekens H. eds.), 1987, 557-562.
11-Boissard, C., Chelbi-Alix, M.K., Gali, P., Thang, M.N. and Rosselin, G.
Mise en evidence du recepteur de l'interferon alpha sur la cellule cancereuse
colique humaine en culture.
C.R. Acad. Sci., 1989, 309, Série III, 485-492.
12-Chelbi-Alix, M.K., Boissard, C., Rosselin, G. and Thang, M.N.
Le peptide intestinal vasoactif induit la 2'5'oligoadénylate synthétase et l'état antiviral
dans les cellules du cancer du colon HT29.
C.R. Acad. Sci., 1990, 310, Série III, 147-153.
13-Chelbi-Alix, M.K., Boissard, C., Sripati, C.E., Rosselin, G. and Thang, M.N.
VIP induces in HT-29 cells 2'5' oligoadenylate synthetase and antiviral state via
interferon a/b synthesis.
Peptides, 1991, 12, 1085-1093.
14-Chelbi-Alix, M.K., Belforte, B., Saal, F., Lasneret, J., Peries, J., and
Thang,M.N.
The effects of poly(I).poly(C12U) and interferon on the multiplication of a
mammalian type C oncornaretroviridae.
J. Gen. Virol., 1992, 73, 2291-2297.
15 -Chelbi-Alix, M.K. and Chousterman, S.
Ethanol induces 2'5'A synthetase and antiviral activities through beta interferon
production.
J. Biol. Chem., 1992, 267, 1741-1745.
16-Chelbi-Alix, M.K. , Pelaparat, D., Boissard, C., Rostène, W., and Thang, M.N.
Induction by Vasoactive Intestinal Peptide of interferon a/b synthesis in glial cells
but not in neurons.
J. Cell. Physiol., 1994, 158, 47-54.
17-M.K. Chelbi-Alix, A. Fournier, D. Pelaparat, C. Boissard, W. Rostène and M.N.
Thang.
Vasoactive Intestinal Peptideis an inducer of interferon a/b synthesis. 1st
international symposium on VIP, PACAP and related regulatory peptides from
molecular biology to clinical applications. G. Rosselin, ed., 1994, pp 598-606.
18-Chelbi-Alix, M.K., and Sripati, C.E.
Effect of insulin and DsRNA to induce interferon system and hsp 70 in fibroblast
and epithelial cells in relation to their effects on cell growth.
Exp. Cell. Res., 1994, 213, 383-390.
19-Koken, M., Linares-Cruz, G., Quignon, F., Chelbi-Alix, M.K., Sobczak-Thépot,
J., Juhlin, L., Degos, L., Calvo, F., and de Thé, H.
The PML growth-suppressor has an altered expression human oncogenesis.
Oncogene, 1995, 10, 1315-1324.
20-Colas, S., Bourrges, J.F., Wybier-Franqui, J., Chelbi-Alix, M.K., Paul, P.,
Emanoil-Ravier, R. Human Foamy infection activates class I major
histocompatibility complex antigen expression.
J. Gen. Virol.,1995, 76, 661-667.
21-Puvion- Dutilleul, F., Chelbi-Alix, M.K., M. Koken, F. Quignon, E. Puvion, H. de Thé.
Adenovirus infection induces rearrangements in the intranuclear distribution of the
nuclear body -associated PML protein.
Exp. Cell. Res., 1995, 218, 9-16.
22-Chelbi-Alix, M.K., L. Pelicano, F. Quignon, M. Koken, M. Stadler, J. Pavlovic, L.
Degos, H. de Thé. Induction of PML by interferons in normal and APL cells.
Leukemia, 1995, 9, 2027-2033.
23-Stadler, M., Chelbi-Alix, M.K., Koken, M.H.M., Venturini, L., Lee, C., Saïb, A.,
Quignon, F., Pelicano, L., Guillemin, M.C., Schindler, C. and de Thé, H. (1995)
Transcriptional induction of the PML growth suppressor gene by interferons is mediated
through an ISRE and a GAS element.
Oncogene, 1995, 11, 2565-2573.
24-Chelbi-Alix, M.K., L. Pelicano, F. Quignon, M. Koken, and H. de Thé (1996).
PML is a primary target gene of interferon and could mediate some of its biological
activities. Tumor Biology. Regulation of Cell Growth Differentiation and Genetics in
Cancer, A. S. Tsiftsoglou, A.C., Sartorelli, D. E., Housman, T.M., Dexter, eds,
1996, Series H : Cell Biology, 99, pp 17-28.
25-André, C., Guillemin, M.C., Zhu J., Koken, M., Quignon, F., Chelbi-Alix, M.K.,
Degos, L., Wang, Z.Y., Chen, Z. and de Thé. The PML and PML/RARa domains : from
autoimmunity to molecular oncology, and from retinoic acid to arsenic.
Exp. Cell. Res., 1997, 229, 253-260.
26-Zhu J., Koken, M., Quignon, F., Chelbi-Alix, M.K., Degos, L., Wang, Z.Y., Chen,
Z., and de Thé. Arsenic-induced PML targeting onto nuclear bodies, implications for
the treatment of acute promyelocytic leukaemia.
Proc. Natl. Acad. Sci. USA, 1997, 94, 3978-3983.
27-Pelicano, L., Li, F., Schindler, C. and M. K. Chelbi-Alix
Retinoic acid induces interferon-induced proteins : Evidence of multiple mechanisms of
action.
Oncogene, 1997, 15, 2349-2359.
28-Koken M., Reid, A., Quignon, F., Chelbi-Alix, M.K., , Dong S., Chen Z., Davies J.,
Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF
heterodimerize and colocalize to nuclear bodies.
Proc. Natl. Acad. Sci. USA, 1997, 94, 10255-10260.
29-Gianni M., Koken MHM., Chelbi-Alix M.K., and de Thé. Isolation and
characterization of an As2O3-resistant NB4 subline : rapid induction of apoptosis by retinoic
acid.
Blood, 1998, 91, 4300-4310.
30-Chelbi-Alix, M.K., Quignon, F., Pelicano, L., Koken, M and de Thé
Virus resistance conferred by the interferon-induced Promyelocytic Leukemia protein.
J. Virol., 1998, 72, 1043-1051.
31-Pelicano, L., and M. K. Chelbi-Alix
L'acide rétinoïque et l'interféron dans le traitement des cancers humains : mécanismes
d'action.
Bulletin du Cancer, 1998, 85, 313-318.
32-Chelbi-Alix M.K., and de Thé
Herpes virus proteasome-dependent degradation of nuclear bodies-associated PML and
Sp100 proteins.
Oncogene, 1999, 18, 935-941.
33-Pelicano L., Brumpt C., Pitha P.M. and Chelbi-Alix M.K .
Retinoic Acid Resistance in NB4 APL cells is associated with lack of Interferon a synthesis, Stat1
and p48 induction.
Oncogene, 1999, 18, 3944-3953.
34- Chelbi-Alix M.K., and L. Pelicano
Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells.
Leukemia, 1999, 13, 1167-1174.
35-Zhu J, Gianni M., Kopf, E., Honore, N., Chelbi-Alix M.K , Koken, M; Quignon F.,
Rochette-Egly, C., and H. de The.
Retinoic acid induces proteasome-dependent degradation of Retinoic acid receptor a
(RARa) and oncogenic RARa fusion proteins.
Proc. Natl. Acad. Sci. USA, 1999, 96, 14807-14812.
36- Puvion-Dutilleul, F., Legrand, V., Mehtali, M., Chelbi-Alix M.K., de The, H., and E.
Puvion.
Deletion of the fiber gene induces the storage of hexon and penton base proteins in
PML/Sp100-containing inclusions during adenovirus infection.
Biology of the cell, 1999, 91, 617-628.
37- Pelicano L. and Chelbi-Alix M.. Interférons : signalisation et clinique. Regard sur la
Biochimie, 1999, 2,15-28.
38- Bazarbachi A. , Nasr R., El-sabban M. E. , Mahe A. , Mahieux A., Mahieux R., Gessain A.,
Darwiche N. , Dbaido G., Kersual J. , Zermati Y. , Dianoux L. , Chelbi-Alix M. , de Thé H. ,
and hermine O. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine
in HTLV-I associated adult T cell leukemia/lymphoma.
Leukemia, 2000,14, 716-721.
39- Vannucchi S, Percario ZA, Chiantore MV, Matarrese P, Chelbi-Alix MK, Fagioli M,
Pelicci PG, Malorni W, Fiorucci G, Romeo G, Affabris E.
Interferon-beta induces S phase slowing via up-regulated expression of PML in squamous
carcinoma cells
Oncogene, 2000, 44, 5041-53, .
40-Regad T,& Chelbi-Alix MK.
Role and fate of PML nuclear bodies in response to interferon and viral infections.
Oncogene. 2001, 49, 7274-86.
41- de The H, & Chelbi-Alix MK
APL, a model disease for cancer therapies?
Oncogene. 2001, 49, 7136-9.
42- Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, de The H, Chelbi-Alix MK
PML mediates the interferon-induced antiviral state against a complex retrovirus via its
association with the viral transactivator.
EMBO J. 2001, 13, 3495-505.
43-Danielle Blondel, Tarik Regad, Nicolas Poisson, Benjamin Pavie, Francis Harper, Pier
P. Pandolfi, Hughes de Thé and Mounira K. Chelbi-Alix
Rabies virus P and small P products interact directly with PML and disrupt PML
nuclear bodies
Oncogene, 2002, 21, 7957-70
44-Regad T, Chelbi-Alix MK.
PML, un nouvel intermédiaire de l'effet antiviral de l'interféron.
Med. Sci, 2002, 18, 25-27
45- Chelbi-Alix MK. Bobe P, Benoit G, Canova A & R Pine Arsenic enhances the
activation of Stat1 by interferon g leading to synergistic expression of IRF-1 Oncogene.
In press 2003.


 
FMSH
 
Facebook Twitter Google+
Mon Compte